郑毅然

姓  名：郑毅然
职称职务：特聘教授, 博士生导师
电子邮箱：yrzheng@suda.edu.cn
办公地址：云轩楼1429

教育经历：

2006.09 – 2009.05: 美国约翰·霍普金斯大学 (Johns Hopkins University)，化学与生物分子工程系；生物系，本科

2010.09 – 2015.11: 美国麻省理工学院 (Massachusetts Institute of Technology)，生物工程系，博士

2017.08 – 2019.07: 新加坡国立大学 (National University of Singapore)，商务分析（大数据；医疗卫生），在职硕士MSBA

科研工作经历：

博士毕业后在新加坡科技研究局生物工程和纳米科技研究所任博士后（2015-2017）和科研员（2017-2019），从事生物工程研究。加入bat365中文官方网站后任特聘教授、博士生导师。多年来结合免疫、肿瘤生物、材料工程和生物科技增强了CAR-T疗效，研发了新型癌症免疫疗法、疫苗和诊断工具。相关技术已在美国、中国、加拿大、欧洲、日本等国申请多项专利，并被美国癌症免疫疗法制药公司收购，成功转化，助力公司融资。基于相关技术的公司旗舰产品，正与默沙东公司合作在美国开展针对血液癌症和实体肿瘤的临床试验，并被美国药监局特批为快速通道项目。

研究方向：

免疫工程（癌症免疫疗法、疫苗）、生物材料、生物微环境响应递药系统、人工智能药物研发

主要荣誉：

2019/2020：国家海外高层次人才；江苏省双创人才；姑苏创新领军人才；金鸡湖高层次人才

2006-2015：全额奖学金在美国约翰·霍普金斯大学和麻省理工学院学习

代表性论文：

1. P. Zhang^#, T. Wang^#, G. Cui^#, R. Ye, W. Wan, T. Liu*, Y. Zheng*, Z. Zhong*. Systemic multifunctional nanovaccines for potent personalized immunotherapy of acute myeloid leukemia, Advanced Materials 2024, DOI: 10.1002/adma.202407189.

2. W. Deng^#, J. Chen^#, X. Wang^#, Q. Wang, L. Zhao, Y. Zhu, J. Yan*, Y. Zheng*. Paravertebrally‐injected multifunctional hydrogel for sustained anti‐inflammation and pain relief in lumbar disc herniation. Advanced Healthcare Materials2024, 2401227, https://doi.org/10.1002/adhm.202401227.

3. W. Wan^#, W. Han^#, J. Chen, Y. Li, L. Zhao, M. Gao, C. Shen, N. Liu, W. Deng, S. Ma, L. Cheng, Y. Zheng*. Chemokine-based injectable navigation system for enhancing CAR-T cell therapy against solid tumors. Advanced Functional Materials 2024, 2401161, https://doi.org/10.1002/adfm.202401161. 封面文章

4. G. Cui, Y Sun, L. Qu, C. Shen, Y. Sun, F. Meng, Y. Zheng*, Z. Zhong*. Uplifting anti-tumor immunotherapy with lymph node-targeted and ratio-controlled co-delivery of tumor cell lysate and adjuvant. Advanced Healthcare Materials2024, 13, 2303690, https://doi.org/10.1002/adhm.202303690.

5. X. Chen, M. Gao, S. An, L. Zhao, W. Han, W. Wan, J. Chen, S. Ma, W. Cai, Y. Cao, D. Ding, Y. Y. Yang, L. Cheng*, Y. Zheng*. Enhancing adoptive T cell therapy for solid tumor with cell-surface anchored immune checkpoint Inhibitor nanogels. Nanomedicine:NBM2022, 45,102591, doi:10.1016/j.nano.2022.102591.

6. Y. Zheng*, Z. Zhong*. Roadmap to next-generation cancer vaccines. Journal of Controlled Release2022, 347, 308-313, doi:10.1016/j.conrel.2022.05.005.封面文章

7. M. He^#, T. Yang^#, Y. Wang, M. Wang, X. Chen, D. Ding*, Y. Zheng*, H. Chen*. Immune Checkpoint Inhibitor‐Based Strategies for Synergistic Cancer Therapy. Advanced Healthcare Materials2021, 10(9): 2002104.

8. Y. Zheng*, J. Kng, C. Yang, J. L. Hedrick, Y. Y. Yang*. Cationic polymer synergizing with chemotherapeutics and re-purposing antibiotics against cancer cells. Biomaterials Science2021, 9, 2174-2182.

9. L. Tang^*#, Y. Zheng^#, M. Melo, L. Mabardi, A. P. Castano, Y.Q. Xie, N. Li, S. B. Kudchodkar, H. C. Wong, E. K. Jeng, M. V. Maus, and D. Irvine^*. Enhancing T-cell therapy through TCR signaling-responsive nanoparticle drug delivery. Nature Biotechnology2018,36 (8), 707. 封面文章；同刊评述 “A backpack revs up T-cell activity” by Shum, Heslop

10. Y. Zheng, L. Tang, L. Mabardi, S. Kumari and D. Irvine. Enhancing adoptive cell therapy of cancer through targeted delivery of small-molecule immunomodulators to internalizing or non-internalizing receptors. ACS Nano2017, 11(3):3089-3100.

11. Y. Zheng, M. T. Stephan, S. A. Gai, W. Abraham, A. Shearer, and D. J. Irvine. In vivo Targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes. Journal of Controlled Release 2013, 172(2):426-35.

12. H. Liu, K. Moynihan, Y. Zheng, G. Szeto, A. Li, B. Huang, D. Egeren, C. Park, D.Irvine.  Structure-based programming of lymph-node targeting in molecular vaccines. Nature2014, 507(7493): 519–522.